Abstract

Alzheimer’s disease (AD) is a serious chronic health problem that causes great pain and loss to patients and their families. Its early and accurate diagnosis would achieve significant progress on the prevention and treatment of the disease. Magnetic Resonance Imaging (MRI) is a commonly used technique in nuclear medical diagnostics. However, it is still a challenging problem to diagnose AD, Control Normal (CN), and Mild Cognitive Impairment (MCI) because of the complex structures of MRI. In this paper, diagnosing models for MRI images are proposed to identify the various stages of AD based on the Broad Learning Systems (BLS), as well as its convolutional variants. To verify the validity of the proposed models, experiments on MRI images collected from the ADNI website are tested and evaluated. The results show that our algorithms outperform the other state-of-the-art algorithms for various tasks with better accuracy and less training times. Finally, the cross-domain learning ability of the proposed algorithms is verified on an independent AD dataset.

Highlights

  • A L zheimer’s disease (AD), the most common dementia, is a complex disease leading to memory impairment and other cognitive problems

  • The state of AD can be divided into three categories: Alzheimer’s disease (AD), mild cognitive impairment (MCI), control normal (CN), of which MCI can be subdivided into stable mild cognitive impairment and progressive mild cognitive impairment [7, 8]

  • The primary goal of ADNI is to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessments subjected to participants could be combined to measure the progression of MCI and early Alzheimer’s disease (AD)

Read more

Summary

INTRODUCTION

A L zheimer’s disease (AD), the most common dementia, is a complex disease leading to memory impairment and other cognitive problems. According to the 2018 World Alzheimer report, nearly 50 million people worldwide were living with dementia in 2018. This number will triple to 152 million by 2050. To diagnose Alzheimer’s disease, it is necessary to comprehensively analyze the patient’s medical history, behavioral assessment, cognitive test, brain imaging, and blood sampling. The patient’s medical history and behavioral assessment are the main clinical diagnostic pieces of evidence. Both medical history and behavioral tests require evaluation by multiple visits of expert doctors for a long period of time.

Result
MATERIALS AND METHODS
METHOD PRELIMINARIES
METHOD PROPOSED
MODEL EVALUATION
MODEL TRANSFER LEARNING
RESULTS OF AD STATE PREDICTION
RESULTS OF AD CLASSIFICATION
2.10 Million
Findings
CONCLUSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call